Asthika Goonewardene
Stock Analyst at Truist Securities
(2.13)
# 2,936
Out of 5,112 analysts
97
Total ratings
40.22%
Success rate
-3.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Buy | $40 | $27.23 | +46.90% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $22.01 | +95.37% | 1 | Nov 25, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Hold | $36 → $31 | $29.03 | +5.92% | 6 | Nov 13, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $32.38 | +48.24% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $124.29 | +16.66% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $21.98 | +77.43% | 2 | Oct 7, 2025 | |
| MRUS Merus | Downgrades: Hold | $88 → $97 | $97.01 | -0.01% | 3 | Sep 29, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $13.79 | +625.16% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $78.78 | +25.67% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $44.30 | +10.61% | 11 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $151 → $155 | $92.50 | +67.57% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $21.92 | +223.91% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $1.42 | +604.23% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.63 | +513.50% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $2.48 | +504.84% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.82 | +96.41% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $136 | $63.96 | +112.63% | 5 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $9.98 | +1,403.01% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.52 | +163.16% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.68 | +1,030.95% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.49 | +5,368.91% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $11.27 | +964.77% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.45 | +4,037.93% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $11.38 | +1,481.72% | 4 | Aug 23, 2022 |
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $27.23
Upside: +46.90%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $22.01
Upside: +95.37%
Mersana Therapeutics
Nov 13, 2025
Downgrades: Hold
Price Target: $36 → $31
Current: $29.03
Upside: +5.92%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $32.38
Upside: +48.24%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $124.29
Upside: +16.66%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $21.98
Upside: +77.43%
Merus
Sep 29, 2025
Downgrades: Hold
Price Target: $88 → $97
Current: $97.01
Upside: -0.01%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $13.79
Upside: +625.16%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $78.78
Upside: +25.67%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $44.30
Upside: +10.61%
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $92.50
Upside: +67.57%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $21.92
Upside: +223.91%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.42
Upside: +604.23%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.63
Upside: +513.50%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $2.48
Upside: +504.84%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $17.82
Upside: +96.41%
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $63.96
Upside: +112.63%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $9.98
Upside: +1,403.01%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.52
Upside: +163.16%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.68
Upside: +1,030.95%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.49
Upside: +5,368.91%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $11.27
Upside: +964.77%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.45
Upside: +4,037.93%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $11.38
Upside: +1,481.72%